1 2 2	Age- and sex-specific differences in immune responses to BNT162b2 COVID-19 and live- attenuated influenza vaccines in UK adolescents
5 4	Cecilia Jay ^{1*} Emily Adland ² Anna Csala ² Nicholas Lim ² Stenhanie Longet ³ Ane Oghe ¹ PITCH
5	Consortium, Jeremy Ratcliff ¹ , Oliver Sampson ⁴ , Craig P Thompson ⁵ , Lance Turtle ⁶ , Eleanor
6	Barnes ^{1,7} , Susanna Dunachie ^{1,7} , Paul Klenerman ^{1,7} , Miles Carroll ^{1,7} , Philip Goulder ^{2*}
7	
8	Affiliations:
9	¹ Nuffield Department of Medicine, University of Oxford, Oxford, UK
10	² Department of Paediatrics, University of Oxford, Oxford, UK
11	³ Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
12	⁴ Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK
13	⁵ Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Warwick,
14	UK
15	⁶ Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool,
16	UK
17	⁷ NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust
18	
19	
20	* Correspondence:
21	Prof. Philip Goulder
22	philip.goulder@paediatrics.ox.ac.uk
23	
24	
25	<u>cecilia.jay@ndm.ox.ac.uk</u>
20 27	
21 20	
20 29	Keywords: SARS-CoV-2 vaccine COVID-19 adolescents immunity

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 Abstract

31 Key to understanding COVID-19 correlates of protection is assessing vaccine-induced 32 immunity in different demographic groups. Sex- and age-specific immune differences have a 33 wide impact on outcomes from infections and immunisations. Typically, adult females make 34 stronger immune responses and have better disease outcomes but suffer more adverse 35 events following vaccination and are more prone to autoimmune disease. To understand 36 better the mechanisms underlying these differences in vaccine responses, we studied 37 immune responses to two doses of BNT162b2 Pfizer COVID-19 vaccine in an adolescent 38 cohort (n=34, ages 12-16), an age group previously shown to make significantly greater 39 immune responses to the same vaccine compared to young adults. At the same time, we were able to evaluate immune responses to the co-administered live attenuated influenza 40 41 vaccine, which has been shown to induce stronger immune responses in adult females. Blood samples from 34 adolescents taken pre- and post-vaccination with COVID-19 and influenza 42 43 vaccines were assayed for SARS-CoV-2-specific IgG and neutralising antibodies, and cellular 44 immunity specific for SARS-CoV-2 and endemic betacoronaviruses. IgG targeting influenza 45 lineages contained in the influenza vaccine was also assessed. As previously demonstrated, 46 total IgG responses to SARS-CoV-2 Spike antigens were significantly higher among vaccinated 47 adolescents compared to adults (aged 32-52) who received the BNT162b2 vaccine 48 (comparing infection-naïve, 49,696 vs 33,339; p=0.03; comparing SARS-CoV-2 previously-49 infected, 743,691 vs 269,985; p<0.0001) by MSD v-plex assay. However, unexpectedly, 50 antibody responses to BNT162b2 and the live-attenuated influenza vaccine were not higher 51 among female adolescents compared to males; among infection-naïve adolescents, antibody 52 responses to BNT162b2 were higher in males than females (62,270 vs 36,951 p=0.008). No 53 sex difference was identified in vaccinated adults. These unexpected findings may result from 54 the introduction of novel mRNA vaccination platforms, generating patterns of immunity 55 divergent from established trends, and providing new insights into what might be protective 56 following COVID-19 vaccination. 57

- 58 Abstract length: 299
- 59 Word length: 4081
- 60 References: 51
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68

69 Introduction

70 The BNT162b2 Pfizer-BioNTech COVID-19 vaccine was authorised for 12-15 year olds in June

71 2021 in the United Kingdom as a 30µg one-dose regimen by the Medicines and Healthcare

72 Products Regulatory Agency.[1] This was extended to a two-dose regimen in early 2022.[2] In

73 the United Kingdom, the first dose of BNT162b2 was administered in adolescents alongside

74 the AstraZeneca intranasal seasonal live-attenuated influenza vaccine (LAIV) FluenzTetra,

- therefore presenting a unique opportunity to study vaccine-induced immunity in this age 75
- 76 group.

77 78 Older age is a primary risk factor for severe COVID-19, perhaps due to the reduced immune 79

capacity with age driven by persistent inflammation and cellular dysfunction.[3] The death 80 rate of COVID-19 is 0.66% overall, increasing to 7.8% in over 80s.[4] The majority of young

81 people experience mild COVID-19; severe disease and multisystem inflammatory syndrome

- 82 only occurs in a minority of paediatric patients.[5] Adolescents and children display rapid and
- 83 adaptable immune responses that may contribute to improved resolution of infections, such
- as abundant IgM memory B-cells, broad and rapidly produced natural antibodies, and lower 84
- 85 inflammatory cytokine responses. [6,7] Differential COVID-19 outcomes between adults and
- 86 children may also be influenced by pre-existing immune responses to endemic coronaviruses
- 87 that might circulate at higher levels in children.[6] Notably, adolescents between 12 and 15
- 88 years of age generate 1.76-fold higher IgG responses to BNT162b2 than 16-25 year olds,
- 89 indicating either potential age-related changes in immune response even during
- 90 adolescence, or an increase in cross-reactivity with endemic coronaviruses that enhances
- 91 vaccine responsiveness and declines with age.[8] Finally, older individuals are more likely to
- 92 have immunodeficiencies or chronic diseases which increase their risk of severe COVID-19.
- 93

94 In addition to age, understanding the role of sex in vaccine response is crucial for developing 95 more effective vaccines. Adult females aged 18-49 have been shown to generate twofold 96 greater antibody responses to trivalent influenza vaccines,[9] and adult females are more at 97 risk for serious adverse events (SAEs) after vaccination, including after the ChAdOx1 Oxford-98 AstraZeneca COVID-19 vaccine. [10–12] In one study, females given half-dose influenza 99 vaccine made marginally stronger antibody responses compared to age-matched males who 100 received full-dose vaccine.[9] Greater vaccine-induced immune responses in females could 101 potentially facilitate reduced dosing regimens for females, which may minimise incidence of

102 SAEs, improve vaccine uptake, and improve vaccine supply. However, young males

- 103 experience more vaccine-induced myocarditis after BNT162b2, suggesting that immune
- 104 responses to mRNA vaccines may be differentially influenced by sex.[13,14] Adolescents
- 105 undergoing puberty face significant changes in levels of sex hormones such as testosterone
- 106 and oestrogen, which are known to modulate immunity to SARS-CoV-2 and influenza.[15,16]
 - 107
 - 108 To explore sex- and age-specific differences in humoral and cellular immunity to BNT162b2,
 - 109 we studied adolescent and adult cohorts in the United Kingdom who received this vaccine.
 - 110 Data collected from adolescents in this study were compared to the Protective Immunity
 - 111 from T-cells in Healthcare Workers (PITCH) cohort of vaccinated healthcare workers (HCWs)
 - 112 aged 32-52, who received two doses of BNT162b2 and also represented a mixture of
 - 113 previously-infected and infection-naïve individuals.[17] We explored age-specific effects on
 - 114 immunity within the adolescent cohort as well as between adolescents and adults.
 - 115 Furthermore, we examined whether sex-specific immune effects were evident. As not all

- adolescents also received the LAIV, we were also able to assess whether co-administration of
- 117 LAIV appeared to influence the magnitude of response to BNT162b2. Furthermore, many
- 118 studies of adolescent responses to BNT162b2 have used prior SARS-CoV-2 infection as an
- 119 exclusion criterion[18,19]. Here, we enrolled both SARS-CoV-2 infection-naïve and previously-
- 120 infected adolescents to understand the role of prior or ongoing infection in vaccine response.

122 Results

123 Cohort description

124 In November and December of 2021, 34 adolescents aged between 12 and 16 were recruited125 into the study through their enrolment at schools in Oxford, UK (Fig. 1A). All 34 individuals

125 into the study through their enrolment at schools in Oxford, or (Fig. 1A). An 34 individuals 126 received the BNT162b2 vaccine; 26 (76%) also received the LAIV on the same day as the first

dose of BNT162b2. 47% of individuals (n=16) were female, and the median age was 14.1

- 128 years (12.2-16) (Fig. 1B). 33 individuals were Caucasian, one individual was Asian. No
- 129 individuals were on any regular medication.
- 130

131 The adult cohort to which adolescent data was compared was the PITCH cohort of vaccinated

- 132 HCWs.[20,21] This cohort consisted of 589 adults aged 32-52 who had received two doses of
- 133 BNT162b2 28 days apart. Here, IgG data from 170 adults and neutralising antibody (nAb) data
- 134 from 10 adults was used to compare to data from adolescents.
- 135
- 136

137 Humoral immune responses to BNT162b2 vaccination

138 To evaluate the immunogenicity of the BNT162b2 vaccine among adolescents, we first

- 139 characterised humoral responses using MSD-platform immunoassays to measure
- 140 quantitatively the total immunoglobulin G (IgG) response to SARS-CoV-2 Spike (S), the
- 141 receptor-binding domain (RBD) of S, and SARS-CoV-2- N (Fig. 2A). Both infection-naïve and
- 142 previously-infected adolescents made significantly greater IgG responses to S post-V1 than
- 143 pre-V1 (61 vs 49,696, x803, p=0.0005 and 13,409 vs 788,568, x55, p<0.0001, respectively,

144 Wilcoxon signed-rank test) and greater anti-RBD IgG responses (263 vs 16,861, x64, p=0.0005

- and 6,556 vs 351,068 x53, p<0.0001, respectively, Wilcoxon signed-rank test) (Fig. 2A). Anti-S
- and RBD IgG responses increased post-V2 in all groups, but only anti-RBD IgG increased
- significantly and only in previously-infected individuals (90,067 vs 318,687, x3.5, p=0.008,
- 148 Wilcoxon signed-rank test). Notably, two doses of BNT162b2 in infection-naïve individuals
- **149** gave similar levels of IgG to one dose of vaccine in previously-infected individuals.
- 150

Since nAbs as well as total IgG are reported to be a correlate of protective immunity against

- symptomatic COVID-19,[22] we next assessed a surrogate of nAb activity using the MSD-
- **153** platform ACE2 inhibition assay,[23] which is well correlated with live virus neutralisation
- assays.[20,21,24,25] In contrast to IgG responses, only previously-infected individuals
- generated increased nAb responses following the first dose of vaccine (6 vs 149, x24,
- p=0.0002, Wilcoxon signed-rank test) (Fig. 2B), and fold change in nAb response to S and RBD
 was higher in previously-infected individuals post-V1 compared to infection-naïve individuals
- **158** (1.1 vs 28, p<0.0001 and 1.3 vs 23, p=0.0002, respectively, Mann-Whitney tests)
- 159 (Supplementary Fig. 1AB). After two doses of BNT162b2, infection-naïve individuals reached
- 160 similar nAb titres to previously-infected individuals after one dose, supporting the idea that
- 161 two doses of vaccine are required for a robust neutralising response in infection-naïve
- 162 individuals.
- 163
- 164 To determine how breadth of nAb response to SARS-CoV-2 variants is impacted by
- **165** vaccination and prior infection, the MSD-platform ACE2 inhibition assay was carried out
- against the common variants of SARS-CoV-2 in both infection-naïve and previously-infected
- 167 individuals (Fig. 2C and Supp. Fig. 2). Notably, previously-infected individuals made broad nAb
- 168 responses against all studied variants following the first dose, whereas high-titre nAb

responses against these variants were only observed following the second dose in infection-naive individuals.

171

172 Cellular immune responses to BNT162b2 vaccination

We next characterised the cellular immune response in adolescents following first and 173 174 second doses of BNT162b2. Proliferation assays measuring the dilution of CellTrace Violet 175 (CTV) stain (Thermo Fisher Scientific, USA) following stimulation of peripheral blood 176 mononuclear cells (PBMCs) with pools of SARS-CoV-2 peptides spanning the S1 and S2 177 regions of S, the membrane protein (M) and N, and the S2 region of endemic human coronaviruses (HCoVs) HCoV-HKU1 and HCoV-OC43 were performed at pre-V1, post-V1, pre-178 179 V2 and post-V2 timepoints (Fig. 3, Supp. Fig. 3, Supp. File 1). In contrast to humoral responses 180 to BNT162b2, SARS-CoV-2-specific CD4+ T-cell proliferative responses were similar in 181 infection-naïve compared to previously-infected individuals after a single dose of vaccine. 182 The T-cell response in previously-infected individuals increased following vaccination, but not 183 significantly, suggesting stable cellular immunity over time. 184 Although T-cell responses to HCoV-OC43 S2 and HCoV-HKU1 S2 were identified in several 185 individuals, particularly previously-infected individuals, there was no significant impact of 186 187 BNT162b2 vaccination on the magnitude of T-cell responses. 188 189 190 Higher magnitude antibody responses to BNT162b2 in adolescents versus adults 191 192 The role of age in immune response to vaccination was of particular interest in this study. To 193 determine whether the responses observed in adolescents to the BNT162b2 vaccine were 194 stronger than those observed in adults, as previously shown, [8] we compared the adolescent 195 data to humoral responses in adults (32-52 years) from the PITCH cohort 28 days after the 196 first dose of BNT162b2 (Fig. 4).[26,27] PITCH is a consortium of universities and UK Health 197 Security Agency (UK HSA) with the aim of characterising infection-acquired and vaccine-198 induced immunity to SARS-CoV-2 in HCWs. Here, as reported for adolescents receiving two 199 vaccines,[18,19] post-V1, infection-naive adolescents generated higher magnitude anti-S IgG 200 responses than infection-naive adults (49,696 vs 33,339, x1.5, p=0.03, Mann-Whitney test) 201 and previously-infected adolescents generated greater anti-S IgG responses than previously-202 infected adults (743,691 vs 269,985, x2.9, p<0.0001, Mann-Whitney test) (Fig. 4A). Post-V1 203 nAb responses did not differ significantly between adolescents and adults (Fig. 4B). 204 205 To investigate why infection-naive adolescents generate relatively weak nAb responses post-206 V1, despite a strong total IgG response, we sought to address the hypothesis that cross-

207 reactive antibody responses to endemic HCoVs might be present at higher levels in infection-

208 naïve adolescents, thereby interfering with the generation of novel SARS-CoV-2-specific

responses to BNT162b2, as has been suggested previously.[28,29] Humoral responses to

HCoVs have been associated with worse COVID-19 outcomes, through the inhibition of novel
 responses to SARS-CoV-2 as a result of immune imprinting or 'original antigenic sin'. [28] Pre-

existing cross-reactive IgG may promote higher magnitude IgG responses to the conserved S2

region of SARS-CoV-2 S following vaccination, whilst it is the less conserved S1 region that is

the target of most neutralising antibodies.[30] Children have been reported to display higher

- immunity to endemic HCoVs than adults,[31] perhaps due to high circulation of viruses inschools.
- 217
- 218 Our data supported the hypothesis that cross-reactive antibody responses to HCoVs are
- associated with weaker vaccine-induced neutralising responses: in this study, the ratio of IgG
- targeting betacoronaviruses HCoV-HKU1 and HCoV-OC43 S to IgG targeting SARS-CoV-2 S
- 221 was significantly higher in infection-naive adolescents versus infection-naive adults (0.4 vs
- 222 0.06, x5.9, p<0.0001; 1.9 vs 0.2, x8.3, p<0.0001, Mann-Whitney tests) and versus previously-
- 223 infected adolescents (0.4 vs 0.04, x10, p<0.0001; 1.9 vs 0.3, x7.1, p<0.0001, Mann-Whitney
- test) post-V1 (Fig. 4CD). Furthermore, the ratio of IgG targeting HCoV-HKU1 and HCoV-OC43
- 225 S to IgG targeting SARS-CoV-2 S was significantly negatively correlated with nAb response
- **226** (HKU1: r=-0.75, p<0.0001; OC43: r=-0.84, p<0.0001) in all adolescents, though this
- significance was lost when adolescents were divided into infection-naïve and previously-infected.
- 229

230 Sex differences in response to BNT162b2 vaccination

- 231 Females typically make stronger IgG responses than males following
- vaccination, [10, 11, 32, 33] including after influenza vaccines. [9, 16] Surprisingly, therefore,
- 233 here, infection-naïve males generated significantly higher post-V1 IgG targeting both SARS-
- **234** CoV-2 S and RBD than females (62,270 vs 36,951, x2, p=0.008; 23,860 vs 11,443, x2, p=0.02,
- respectively, Mann-Whitney tests) (Fig. 5AB). There was no significant difference in IgG
- response between the sexes in previously-infected individuals (Fig. 5CD). Furthermore, there
- was a trend towards a stronger RBD and S nAb response post-V1 in infection-naive males
- compared to infection-naive females, although this was not significant (p=0.07 and p=0.15,
- 239 respectively, Mann-Whitney tests) (Fig. 5EF). There was no significant different in baseline
- 240 IgG responses between males and females. There was no sex difference in the humoral
- 241 response to BNT162b2 in adults.[26]
- 242
- 243 A potential mediator of immune sex differences is the effect of sex hormones. Males enter
- 244 puberty on average 2 years later than females. To ensure males in this cohort had entered
- 245 puberty, steroid hormones including testosterone, dihydrotestosterone (DHT) and
- **246** progesterone were measured by Tandem mass spectrometry; these data are the focus of a
- future publication. All but the two youngest males (12 years 2 months and 12 years 10
- 248 months) demonstrated pubertal androgen levels. Testosterone correlated with age in males249 only (r=0.47, p=0.05).
- 249 o 250

251 Humoral responses to LAIV administration

- As well as the immune response to BNT162b2, co-administration of the LAIV enabled the
- 253 characterisation of immunity against influenza following vaccination. To determine the effect
- of the LAIV on lineage-specific anti-haemagglutinin (HA) IgG titres, enzyme-linked
- immunosorbent assays (ELISAs) were performed on pre- and post-LAIV samples for the 26
- individuals who received the LAIV (Fig. 6). As expected, IgG titres were significantly higher
- 257 post-LAIV for A/Cambodia (H3N2), A/Victoria (H1N1), and B/Phuket (Yamagata) (9.3 vs 13.9,
- 258 x1.5, p<0.0001; 11 vs 13.4, x1.2, p=0.0002; 7 vs 10.2, x1.5, p<0.0001; respectively, Wilcoxon
- signed-rank tests) (Fig. 6A). Surprisingly, post-LAIV anti-HA IgG responses towards the
- 260 B/Washington (Victoria) lineage were not significantly increased compared to pre-LAIV. A
- 261 possible explanation lies in the observation that responses to B/Washington (Victoria) were

262 strongly correlated with age for both pre- and post-vaccine timepoints (r=0.61, p=0.0001,

- 263 r=0.57, p=0.0008, respectively, Spearman rank test) (Fig. 6BC). By contrast, there was no
- 264 correlation between age and post-LAIV IgG for A/Cambodia (H3N2) or B/Phuket (Yamagata), 265 and for A/Victoria (H1N1) pre-LAIV IgG levels only were weakly correlated with age (r=0.39,
- 266 p=0.02, Spearman rank test). This pattern suggests that natural exposure to B/Washington
- 267 (Victoria) is so frequent in this cohort that vaccination against this strain of influenza does not
- 268 add significantly to the natural immunity that is accumulated over adolescence. Pre-existing
- 269 immunity to influenza has been widely described, from prior infection and vaccination, in
- 270 support of this finding. [34,35]
- 271

272 Unexpectedly, and in contrast to previous studies, [36] adolescents previously-infected with

- 273 SARS-CoV-2 who received both BNT162b2 and the LAIV generated significantly higher post-
- 274 V1 IgG targeting both S and RBD compared to adolescents previously-infected with SARS-275
- CoV-2 who received BNT162b2 alone (286,185 vs 817,284, x2.8, p=0.01; 159,101 vs 379,429,
- 276 x2.3, p=0.01, Mann-Whitney tests), although this analysis involved very small numbers of 277 individuals (Fig. 6DE). We did not find a sex difference in the IgG response to the LAIV (Fig 6F-
- 278 1).

279

Discussion 280

- Understanding the quantitative markers of vaccine immunogenicity, as well as confounding 281 282 patient demographic factors, will help better define correlates of protection against SARS-283 CoV-2 and improve interpretability of future vaccine trials. Due to the discrepancy between 284 IgG and nAb response in infection-naive adolescents, these data support the use of nAb titre
- 285 as well as total IgG when assessing vaccine immunogenicity.[37,38] Other studies have
- 286 established that BNT162b2 and the CoronaVac inactivated virus vaccine elicit robust nAb
- 287 responses post-V2 in infection-naive adolescents. [19,39] The totality of data described herein
- 288 suggest that a robust nAb response is prompted in infection-naive adolescents after two
- 289 doses but previously-infected adolescents only require one dose. Previous studies in adults
- 290 have differed in their evaluation of vaccine-induced versus infection-induced humoral
- 291 immunity, but these data show that a similar IgG response is elicited in adolescents after
- natural infection and one vaccine dose compared to two vaccine doses only.[40] The 292 293 longevity of these responses is uncertain due to the lack of an extended follow up in this
- 294 cohort but should be the focus of future studies.
- 295
- 296 Other research has shown that two doses of BNT162b2 elicit robust T_H1 T-cell responses in 297 adults, with widespread interferon-gamma (IFN γ) production.[26,41] S-specific T-cell 298 responses following vaccination with BNT162b2 were generated post-V2, but not post-V1, in 299 another cohort of infection-naive adolescents.[18] This contrasts with the data described 300 herein, where one dose of BNT162b2 is sufficient to induce a significant increase in S-specific 301 CD4+ T-cells in infection-naive adolescents. The lack of a significant reduction in T-cell 302 response across timepoints suggests that these responses are stable over several months, as 303 reported elsewhere.[42,43] Similarly to the IgG response, SARS-CoV-2-specific T-cell 304 responses post-V1 in previously-infected individuals reach similar frequencies to post-V2 in 305 infection-naive individuals.
- 306
- 307 BNT162b2 has been shown to promote greater IgG production in adolescents compared to 308 adults post-V1.[18] Similarly, here, both infection-naive and previously-infected adolescents

309 generated stronger IgG responses than adults. This may result from higher exposure to 310 endemic HCoVs in adolescents, promoting a stronger IgG response to conserved SARS-CoV-2 311 antigens. However, only previously-infected adolescents generated a strong and broad nAb 312 response targeting multiple variants, and infection-naïve adolescents appeared to rely more 313 on cross-reactive antibodies following their first dose of BNT162b2 compared to both 314 infection-naïve adults and previously-infected adolescents. One interpretation for these 315 patterns is immune imprinting, wherein prior exposure to circulating endemic coronaviruses negatively impacts vaccine-induced immunity. Higher levels of cross-reactive IgG have been 316 317 described in children compared to adults, [31,44,45] and this may result in a stronger 318 memory B-cell response that is weakly neutralising following the first dose of BNT162b2 in 319 infection-naive adolescents. In previously-infected adolescents, prior exposure to SARS-CoV-2 320 may overcome immune imprinting and enable a robust nAb response. This is supported by 321 the strong negative correlation between HCoV:SARS-CoV-2 IgG ratio and nAb response. 322 323 Immune responses to many adult and childhood vaccines, as well as responses to natural 324 infection with viral pathogens, are consistently higher in females and associated with 325 increased inflammation and autoimmunity as well as CD4+-skewed T-cell responses and 326 greater B cell activation and IgG production. [10,11,32,33] Female IgG responses to influenza 327 vaccines have been shown to reach twice the magnitude of male IgG responses, and females 328 also report more frequent SAEs to viral vaccines.[11,33] One exception to this trend is COVID-329 19 mRNA vaccines, for which vaccine-induced myocarditis is more frequent in young males. 330 [13,14,46] Notably, in this cohort, we observe increased post-V1 anti-S and anti-RBD IgG 331 responses in infection-naive males compared to infection-naive females, in contrast to 332 expectations based on other vaccines such as inactivated influenza vaccines.[9,11] We did 333 not observe a significant sex difference in anti-HA IgG titres following the LAIV - this is 334 surprising in the context of established literature, [10,11] but may be obscured by the very

small increase in anti-HA IgG post-V1 in this cohort, the effect of a live-attenuated rather
than inactivated influenza vaccine, the use of different serological assays, or the result of coadministration with BNT162b2.[47] Furthermore, there was no sex difference in anti-SARSCoV-2 IgG for either infection-naïve or previously-infected adults from the PITCH dataset.

339

340 A potential confounder for this study is that adolescents of this age group are likely at 341 different stages of puberty and therefore have diverse levels of testosterone, oestrogen and 342 progesterone. Furthermore, males experience puberty at older ages compared to females, 343 and therefore the sex difference identified herein may result from the confounding effects of 344 puberty. If many male adolescents had not gone through puberty at the time of sampling, the 345 increased humoral responses to vaccination in males may result from an absence of the 346 immunosuppressive effects of androgens. Steroid hormones were measured in this cohort, 347 and although these results are the focus of a future publication, it was identified that all but 348 two males had pubertal levels of testosterone. This promotes confidence in the results of 349 comparisons between sexes, as the majority of males had undergone puberty at time of 350 sampling.

351

352 Finally, the correlation between B/Washington influenza IgG responses with age in 12–16-

- 353 year-olds, as well as the lack of anti-B/Washington HA IgG boosting following the LAIV,
- 354 suggests recent exposure to the B/Washington strain of influenza in this cohort. Our findings
- that co-administration of BNT162b2 with the LAIV improves IgG response in previously-

infected individuals is in contrast with findings for NVX-COV2373, where co-administration

- **357** with inactivated quadrivalent influenza vaccines reduced SARS-CoV-2-specific IgG titres[36].
- **358** However, studies of co-administration of COVID-19 mRNA vaccines with quadrivalent
- influenza vaccines in adults have reported no reduction in antibody response compared to
- administration of mRNA vaccines alone.[48,49] A potential explanation for improved anti-S
- **361** IgG responses following co-administration may be increased innate immune activation due to
- intranasal LAIV administration, particularly in the nasal mucosa, leading to greater SARS-CoV-
- **363** 2-specific local T-helper cell activation.
- 364
- 365 This study has some limitations. The small numbers of adolescents assayed in this cohort
- 366 make broad conclusions difficult, particularly when making comparisons between small sub-
- **367** groups such as co-administered LAIV/BNT162b2 and BNT162b2-alone individuals. No
- 368 mucosal samples were taken and so mucosal immunity is not assessed in this cohort.
- **369** Neutralisation responses to SARS-CoV-2 were estimated using the MSD-ACE2 inhibition
- assay. This has shown to correlate with live virus assays, [20,21,24] but live virus
- 371 neutralisation is likely a more accurate measure of nAbs. In addition, no neutralisation assays
- were carried out for influenza lineages, which would have shed further light on the
- 373 functionality of humoral immunity to influenza. Furthermore, the lack of an extended follow-
- up in this study makes assessments of immune durability impossible but should be the focus
- of future studies.
- 376
- 377 Taken together, these data paint a complex picture of vaccine-induced immunity in
- adolescents, with a potential role for immune sex and age differences in determining
- antibody responses to vaccination. These findings have important implications for paediatric
- 380 vaccination regimes, such as the potential benefit of co-administration with influenza
- 381 vaccines, and the necessity to consider sex and age when studying vaccine-induced
- immunity.
- 383

384 Materials and Methods

385

386 Ethics

387 This longitudinal cohort study was conducted from November 2021 to February 2022. Eligible participants were healthy adolescents aged 12-16 were who either had no history of SARS-388 CoV-2 infection or had experienced mild disease prior to enrolment. Eligible participants 389 390 were identified via their participation in school-based vaccination events. Written informed 391 consent was obtained from all patients and ethical approval was given by the Central 392 University Research Ethics Committee (reference: CUREC R71346/RE001). 32–52-year-old 393 healthy HCWs were recruited as part of the PITCH consortium of HCWs under the GI Biobank 394 Study 16/YH/0247, approved by the research ethics committee (REC) at Yorkshire & The 395 Humber - Sheffield Research Ethics Committee on 29 July 2016, which has been amended for

- this purpose on 8 June 2020.
- 397

398 Sample collection and processing

For the BNT162b2 vaccination (dose 1 (V1) and dose 2 (V2)), patients received 30 ug of
vaccine intramuscularly. LAIV was administered immediately after V1 only; patients received
0.1mL intranasally in both nostrils. Whole blood samples from all 34 individuals were taken

- 402 immediately before V1 (sample pre-V1). Samples from all 34 individuals were taken a mean
- 403 of 37 days after V1 (33-39]) (sample post-V1), from 23 individuals 2 days before V2 (0-8) and
- 404 96 days after V1 (81-114) (sample pre-V2), and from 14 individuals 35 days after V2 (30-40)
- 405 (sample post-V2). All whole blood samples were processed the same day as collection as
- described in the methods. All serum samples were tested for anti-Spike (S) and anti-
- 407 nucleocapsid (N) IgG; individuals were classified as seropositive if their anti-N IgG titre was
- 408 above the previously determined MSD immunoassay cut-off at any point in the study or if
- 409 their anti-spike (S) IgG titre was above the cut-off pre-V1[26]. The percentage of seropositive410 patients increased from 52% to 71% over the course of the study.
- 411
- 412 Whole blood samples were transported from their collection site to an academic laboratory
- 413 and processed the same day. PBMCs and plasma were isolated as described elsewhere[51].
- 414 Briefly, PBMCs were isolated using Lymphoprep (1.077 g/ml, Stem Cell Technologies) through
- 415 density gradient centrifugation. Plasma and PBMCs were collected and plasma was spun at
- 416 2000g for 10 minutes to remove platelets. PBMCs were washed twice with RPMI 1640
- 417 (Sigma, USA) containing 10% heat inactivated foetal calf serum, 2mM L-Glutamine and 1mM
- 418 penicillin/streptomycin (Sigma). An estimated ten million cells were resuspended in media
- 419 and counted using a Muse Cell Analyser (Luminex Corporation, USA). Plasma and PBMCs
- 420 were frozen and stored at 80°C for later use. Steroid hormone concentrations were
- 421 quantified by tandem mass spectrometry by collaborators at Imperial College London.
- 422

423 MSD serological assays

- 424 IgG responses to SARS-CoV-2 S, N and RBD as well as the S proteins of HCoV-OC43, HCoV-
- 425 NL63, HCoV-229E, HCoV-HKU1, SARS-CoV-1 and MERS-CoV were measured using a Meso
- 426 Scale Diagnostics (MSD) V-plex immunoassay 'Coronavirus panel 3' (MSD, USA) according to
- 427 the manufacturer's protocol. Plates were incubated in Blocker A solution for 30 minutes at
- 428 room temperature (RT) with shaking at 700rpm. Plasma or serum was diluted at 1:1000 and
- 429 1:10000 in Diluent 100, and a seven-point standard curve of MSD reference standard
- 430 beginning at 1:10 was prepared in duplicate. Three internal controls and an in-house control

431 of convalescent serum were also used, with Diluent 100 used as a blank. Plates were washed

- 432 three times with MSD Wash Buffer and samples and standards added to the plate before
- 433 incubation at RT for two hours with shaking at 700rpm. Plates were washed three times with
- 434 MSD Wash Buffer and detection antibody solution was added. Plates were incubated for one435 hour at RT with shaking at 700rpm. Plates were washed three times with MSD Wash Buffer.
- hour at RT with shaking at 700rpm. Plates were washed three times with MSD Wash BuffeNeat MSD Gold Read Buffer was added, and plates were read immediately on a MESO
- 430 Near MSD Gold Read Burlet was added, and plates were read infinediately of a MESO437 QuickPlex SQ 120 (MSD, USA). Data was analysed using MSD Discovery Workbench software.
- 438 Thresholds for seropositivity were taken from analyses of pre-pandemic sera, as published
- 439 elsewhere[26], and defined as 1160 AU/ml for SARS-CoV-2 S, 1169 for RBD, and 3874 for N.
- 440
- 441 nAb titres were quantified using Meso Scale Diagnostics ACE2 inhibition assays, 'Panel 27',
 442 (analytes: SARS-CoV-2 S, SARS-CoV-2 S (B.1.351), SARS-CoV-2 S (B.1.617.2; AY.4), SARS-CoV-2
- **443** S (BA.2), SARS-CoV-2 S (BA.2.12.1), SARS-CoV-2 S (BA.2+L452M), SARS-CoV-2 S (BA.2+L452R),
- 444 SARS-CoV-2 S (BA.3), SARS-CoV-2 S (BA.4), SARS-CoV-2 S (BA.5)) according to the
- 445 manufacturer's instructions. Plates were incubated in Blocker A solution for 30 minutes at RT
- 446 with shaking at 700rpm. Serum was diluted at 1:10 and 1:100, and a seven-point standard
- 447 curve of MSD calibration reagent was prepared with 4-fold serial dilutions. Plates were
- 448 washed three times with MSD Wash Buffer and samples and calibrator were added to the
- 449 plate. Plates were incubated at RT for one hour with shaking at 700rpm. Sulfo tagged ACE2
- 450 protein was added to the plate and incubated at RT for one hour with shaking at 700rpm.
- 451 Plates were washed three times with MSD Wash Buffer and MSD Gold Read Buffer was
- 452 added. Plates were read immediately on a MESO QuickPlex SQ 120 (MSD, USA). Data was453 analysed using MSD Discovery Workbench software.
- 454

455 Influenza ELISA assay

- 456 IgG responses to influenza A/Victoria (H1N1), B/Washington (Victoria), A/Cambodia (H3N2),
- 457 and B/Phuket (Yamagata) HA antigens were measured using an indirect ELISA. HA antigens
- 458 (The Native Antigen Company, Oxford) were diluted to 1ug/ml in PBS and used to coat 535
- 459 Nunc-Immuno 96-well plates (Thermo Fisher Scientific, USA) overnight at 4°C
- 460 (A/Victoria/2570/2019 (H1N1)pdm09-like virus (NCBI Accession Number: EPI1799581),
- 461 amino acids 1-528 and C-terminal His-tag; Cambodia/e0826360/2020 (H3N2)-like virus (NCBI
 462 Accession Number: EPI1799580), amino acids 46-469 and C-terminal His-tag;
- 463 B/Washington/02/2019 (B/Victoria lineage)-like virus (NCBI Accession Number: EPI1846769),
- 464 amino acids 31-469 and C-terminal His-tag, B/Phuket/3073/2013 (B/Yamagata Lineage)-Like
- 465 virus] (NCBI Accession Number: EPI1799823), amino acids 44-466 and C-terminal His-tag)
- **466** Plates were washed three times in 0.1% PBS-Tween, before blocking with Casein-PBS Buffer
- 467 for one hour at RT. Plasma was diluted 1:200 in Casein-PBS Buffer and added to plates in
- 468 duplicate. A ten-point standard curve of pooled highly reactive sera beginning at 1:25 was
- 469 prepared in duplicate and added to plates. Casein-PBS Buffer was used as a negative control.
 470 Plates were incubated for two bours at PT and washed six times in 0.1% PBS. Two are
- 470 Plates were incubated for two hours at RT and washed six times in 0.1% PBS-Tween.
 471 Secondary antibody, goat anti-burgar laC appingeted to all all a places between (Circuit)
- **471** Secondary antibody goat anti-human IgG conjugated to alkaline phosphatase (Sigma, USA)
- 472 was diluted 1:1000 in Casein-PBS Buffer and added to plates. Plates were incubated for one 472 hour at PT before washing six times in 0.1% PBS. Tween 4 pitraphenul pheephete in
- 473 hour at RT before washing six times in 0.1% PBS-Tween. 4-nitrophenyl phosphate in
- 474 diethanolamine buffer (Pierce, Loughborough, UK) was added as a substrate and plates were475 incubated for 15 minutes. 405nm absorbance was read using an ELx800 microplate reader
- 476 (Cole Parmer, London, UK).
- 477

478 479

480 Proliferation assay

481 T-cell responses were assayed using a CellTrace Violet Proliferation assay as described

- elsewhere[51]. Cryopreserved PBMCs were thawed in 30mL RPMI containing 10% human AB
- 483 serum (Sigma), 2mM L-Glut and 1mM Pen-Strep. Cells were washed twice with PBS and
- 484 stained with CellTrace Violet (Life Technologies) at 2.5uM for 10 minutes at RT. Cold FCS was
- added to quench the reaction. Cells were plated at 250,000 cells per well in a 96-well round-
- bottom plate. Peptide pools covering SARS-CoV-2 S1, S2, M and N, as well as HCoV-OC43 and
- 487 HCoV-HKU1 S, were added to stimulate cells at a final concentration of 1ug/ml (Mimotopes,
 488 USA) (Supplementary File 1). Media containing 0.1% DMSO (Sigma) was used as a negative
- 489 control. Phytohaemagglutinin L (Sigma) was used as a positive control at a final concentration
- 490 of 2 ug/ml. Plates were incubated at 37°C, 5% CO2, 95% humidity for 7 days, with a
- 491 hemimedia change at day 4. On day 7, cells were washed in PBS and stained with
- 492 fluorochrome-conjugated antibodies for CD4, CD8, and CD3 in PBS. LIVE/DEAD Fixable Aqua
- 493 was used as a viability marker (Thermo Fisher). Cells were fixed in 4% paraformaldehyde
- 494 (Sigma) for ten minutes at 4°C and washed in PBS before storing at 4°C in the dark before
- 495 being run on an MACSquant X (Miltenyi). Gating strategy can be viewed in Supp. Fig. 8.
- 496

497 Statistical analysis

- All analyses were performed in GraphPad Prism 9.0. For pairwise comparisons, two-tailed
 Mann-Whitney tests were used for unpaired data and Wilcoxon signed-rank tests for paired
 data. For correlations, Spearman rank tests were used.
- 501

502 Contributions

- 503 CJ: Conceptualisation, Formal analysis, Investigation, Writing Original Draft Preparation,
- 504 Review & Editing, Visualisation EA: Investigation, Data Curation, Writing Review & Editing,
- 505 Project administration AC: Investigation, Data Curation, Writing Review & Editing, Project
- administration NL: Investigation, Writing Review & Editing SL: Formal analysis,
- 507 Investigation, Writing Review & Editing AO: Investigation, Writing Review & Editing JR:
- 508 Writing Review & Editing OS: Investigation, Writing Review & Editing PITCH Consortium:
- 509 Investigation, Formal analysis, Data Curation CT: Resources, Writing Review & Editing,
- 510 Methodology EB: Conceptualization, Writing Review & Editing, SD: Supervision, Writing –
- 511 Review & Editing LT: Supervision PK: Supervision, Writing Review & Editing,
- 512 Conceptualization, Methodology MC: Supervision, Writing Review & Editing, Methodology
- 513 PG: Conceptualization, Methodology, Resources, Writing Review & Editing, Supervision,
- 514 Project administration, Funding acquisition
- 515

516 Funding

- **517** P.K. is is funded by WT109965MA and is an NIHR Senior Investigator. S.J.D. is funded by an
- 518 NIHR Global Research Professorship (NIHR300791). E.B. Is funded by an NIHR Senior
- 519 Investigator award; the views expressed do not represent those of the NIHR or the NHS. The
- 520 PITCH consortium was funded by the UK Department of Health and Social Care and UKRI
- 521 (MR/W02067X/1), with contributions from UKRI/NIHR through the UK Coronavirus
- 522 Immunology Consortium (MR/V028448/1), the Huo Family Foundation and The National
- 523 Institute for Health Research (UKRIDHSC COVID-19 Rapid Response Rolling Call, Grant
- 524 Reference Number COV19-RECPLAS).

525

526 Acknowledgements

527 We are grateful to staff at the schools from which the participants were enrolled and to the

528 participants and their families.

529

530 The authors declare no competing interests.

532 References

- The MHRA concludes positive safety profile for Pfizer/BioNTech vaccine in 12- to 15 year-olds. In: GOV.UK [Internet]. [cited 21 Oct 2022]. Available:
 https://www.gov.uk/government/news/the-mbra-concludes-positive-safety-profile-
- https://www.gov.uk/government/news/the-mhra-concludes-positive-safety-profile for-pfizerbiontech-vaccine-in-12-to-15-year-olds
- 537 2. COVID-19 vaccination: a guide to a second dose for young people aged 16 to 17. In:
 538 GOV.UK [Internet]. [cited 21 Oct 2022]. Available:
- 539 https://www.gov.uk/government/publications/covid-19-vaccination-resources-for-
- 540 children-and-young-people/covid-19-vaccination-a-guide-to-a-second-dose-for-young-541 people-aged-16-to-17
- Bartleson JM, Radenkovic D, Covarrubias AJ, Furman D, Winer DA, Verdin E. SARS-CoV-2,
 COVID-19 and the aging immune system. Nat Aging. 2021;1: 769–782.
 doi:10.1038/s43587-021-00114-7
- Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the
 severity of coronavirus disease 2019: a model-based analysis. The Lancet Infectious
 Diseases. 2020;20: 669–677. doi:10.1016/S1473-3099(20)30243-7
- 5. Kabeerdoss J, Pilania RK, Karkhele R, Kumar TS, Danda D, Singh S. Severe COVID-19,
 multisystem inflammatory syndrome in children, and Kawasaki disease: immunological
 mechanisms, clinical manifestations and management. Rheumatol Int. 2021;41: 19–32.
 doi:10.1007/s00296-020-04749-4
- 552 6. Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the
 553 proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2
 554 infections. Arch Dis Child. 2021;106: 429–439. doi:10.1136/archdischild-2020-320338
- Carsetti R, Quintarelli C, Quinti I, Mortari EP, Zumla A, Ippolito G, et al. The immune
 system of children: the key to understanding SARS-CoV-2 susceptibility? The Lancet
 Child & Adolescent Health. 2020;4: 414–416. doi:10.1016/S2352-4642(20)30135-8
- Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety,
 Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. New
 England Journal of Medicine. 2021;385: 239–250. doi:10.1056/NEJMoa2107456
- Engler RJM, Nelson MR, Klote MM, VanRaden MJ, Huang C-Y, Cox NJ, et al. Half- vs Full Dose Trivalent Inactivated Influenza Vaccine (2004-2005): Age, Dose, and Sex Effects
 on Immune Responses. Archives of Internal Medicine. 2008;168: 2405–2414.
 doi:10.1001/archinternmed.2008.513
- 565 10. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and Gender Differences in the Outcomes
 566 of Vaccination over the Life Course. Annu Rev Cell Dev Biol. 2017;33: 577–599.
 567 doi:10.1146/annurev-cellbio-100616-060718
- 568 11. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:
 569 626–638. doi:10.1038/nri.2016.90

570 12. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety 571 and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a 572 preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 573 2020;396: 467-478. doi:10.1016/S0140-6736(20)31604-4 574 13. Bozkurt B, Kamat I, Hotez PJ. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 575 2021;144: 471-484. doi:10.1161/CIRCULATIONAHA.121.056135 576 14. Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Collins JS, et al. Symptomatic 577 Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. 578 Pediatrics. 2021;148: e2021052478. doi:10.1542/peds.2021-052478 579 15. Li F, Boon ACM, Michelson AP, Foraker RE, Zhan M, Payne PRO. Estrogen hormone is an 580 essential sex factor inhibiting inflammation and immune response in COVID-19. Sci 581 Rep. 2022;12: 9462. doi:10.1038/s41598-022-13585-4 582 16. Furman D, Hejblum BP, Simon N, Jojic V, Dekker CL, Thiébaut R, et al. Systems analysis of 583 sex differences reveals an immunosuppressive role for testosterone in the response to 584 influenza vaccination. PNAS. 2014;111: 869–874. doi:10.1073/pnas.1321060111 585 17. Angyal A, Longet S, Moore SC, Payne RP, Harding A, Tipton T, et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive 586 UK health-care workers: a multicentre prospective cohort study. The Lancet Microbe. 587 2022;3: e21-e31. doi:10.1016/S2666-5247(21)00275-5 588 589 18. Rosa Duque JS, Wang X, Leung D, Cheng SMS, Cohen CA, Mu X, et al. Immunogenicity 590 and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy 591 adolescents. Nat Commun. 2022;13: 3700. doi:10.1038/s41467-022-31485-z 592 19. Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, 593 Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. New 594 England Journal of Medicine. 2021;385: 239–250. doi:10.1056/NEJMoa2107456 595 20. Angyal A, Longet S, Moore SC, Payne RP, Harding A, Tipton T, et al. T-cell and antibody 596 responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive 597 UK health-care workers: a multicentre prospective cohort study. The Lancet Microbe. 598 2022;3: e21-e31. doi:10.1016/S2666-5247(21)00275-5 599 21. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al. Immunogenicity 600 of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell. 2021;184: 601 5699-5714.e11. doi:10.1016/j.cell.2021.10.011 22. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection 602 603 against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27: 2032-2040. doi:10.1038/s41591-021-01540-1 604 605 23. Smith TRF, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al. Immunogenicity of a DNA 606 vaccine candidate for COVID-19. Nat Commun. 2020;11: 2601. doi:10.1038/s41467-607 020-16505-0

- 608 24. Skelly DT, Harding AC, Gilbert-Jaramillo J, Knight ML, Longet S, Brown A, et al. Two doses
 609 of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2
 610 variants of concern. Nat Commun. 2021;12: 5061. doi:10.1038/s41467-021-25167-5
- 611 25. Grunau B, Prusinkiewicz M, Asamoah-Boaheng M, Golding L, Lavoie PM, Petric M, et al.
 612 Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies
 613 and ACE-2 Inhibition among Vaccinated Individuals. Tripp RA, editor. Microbiol Spectr.
 614 2022;10: e01315-22. doi:10.1128/spectrum.01315-22
- 615 26. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al. Immunogenicity
 616 of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell. 2021;184:
 617 5699-5714.e11. doi:10.1016/j.cell.2021.10.011
- 27. Angyal A, Longet S, Moore S, Payne RP, Harding A, Tipton T, et al. T-Cell and Antibody
 Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and
 Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational
 Cohort Study. Rochester, NY: Social Science Research Network; 2021 Mar. Report No.:
 ID 3812375. doi:10.2139/ssrn.3812375
- 623 28. McNaughton AL, Paton RS, Edmans M, Youngs J, Wellens J, Phalora P, et al. Fatal COVID624 19 outcomes are associated with an antibody response targeting epitopes shared with
 625 endemic coronaviruses. JCI Insight. 2022;7: e156372. doi:10.1172/jci.insight.156372
- 626 29. Beretta A, Cranage M, Zipeto D. Is Cross-Reactive Immunity Triggering COVID-19
 627 Immunopathogenesis? Front Immunol. 2020;11. doi:10.3389/fimmu.2020.567710
- 30. Hurlburt NK, Homad LJ, Sinha I, Jennewein MF, MacCamy AJ, Wan Y-H, et al. Structural
 definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit. Commun
 Biol. 2022;5: 1–13. doi:10.1038/s42003-022-03262-7
- 31. Murray SM, Ansari AM, Frater J, Klenerman P, Dunachie S, Barnes E, et al. The impact of
 pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses.
 Nat Rev Immunol. 2022; 1–13. doi:10.1038/s41577-022-00809-x
- 634 32. Furman D, Hejblum BP, Simon N, Jojic V, Dekker CL, Thiébaut R, et al. Systems analysis of
 635 sex differences reveals an immunosuppressive role for testosterone in the response to
 636 influenza vaccination. Proceedings of the National Academy of Sciences. 2014;111:
 637 869–874. doi:10.1073/pnas.1321060111
- 638 33. Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine639 induced humoral immunity. Semin Immunopathol. 2019;41: 239–249.
 640 doi:10.1007/s00281-018-0726-5
- 34. Wheatley AK, Kent SJ. Prospects for antibody-based universal influenza vaccines in the
 context of widespread pre-existing immunity. Expert Review of Vaccines. 2015;14:
 1227–1239. doi:10.1586/14760584.2015.1068125
- 35. Wild K, Smits M, Killmer S, Strohmeier S, Neumann-Haefelin C, Bengsch B, et al. Pre existing immunity and vaccine history determine hemagglutinin-specific CD4 T cell and

646 IgG response following seasonal influenza vaccination. Nat Commun. 2021;12: 6720.
647 doi:10.1038/s41467-021-27064-3

- 36. Toback S, Galiza E, Cosgrove C, Galloway J, Goodman AL, Swift PA, et al. Safety,
 immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered
 with seasonal influenza vaccines: an exploratory substudy of a randomised, observerblinded, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. 2022;10:
 167–179. doi:10.1016/S2213-2600(21)00409-4
- 37. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
 antibody levels are highly predictive of immune protection from symptomatic SARSCoV-2 infection. Nat Med. 2021;27: 1205–1211. doi:10.1038/s41591-021-01377-8
- 38. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al.
 Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine.
 2021;39: 4423–4428. doi:10.1016/j.vaccine.2021.05.063
- 39. Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z, et al. Safety, tolerability, and immunogenicity
 of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents:
 a double-blind, randomised, controlled, phase 1/2 clinical trial. The Lancet Infectious
 Diseases. 2021;21: 1645–1653. doi:10.1016/S1473-3099(21)00319-4
- 40. Milne G, Hames T, Scotton C, Gent N, Johnsen A, Anderson RM, et al. Does infection
 with or vaccination against SARS-CoV-2 lead to lasting immunity? The Lancet
 Respiratory Medicine. 2021;9: 1450–1466. doi:10.1016/S2213-2600(21)00407-0
- 41. Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. BNT162b2
 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature.
 2021; 1–10. doi:10.1038/s41586-021-03653-6
- 42. Guerrera G, Picozza M, D'Orso S, Placido R, Pirronello M, Verdiani A, et al. BNT162b2
 vaccination induces durable SARS-CoV-2–specific T cells with a stem cell memory
 phenotype. Science Immunology. 2021;6: eabl5344. doi:10.1126/sciimmunol.abl5344
- 43. Moore SC, Kronsteiner B, Longet S, Adele S, Deeks AS, Liu C, et al. Evolution of long-term
 vaccine-induced and hybrid immunity in healthcare workers after different COVID-19
 vaccine regimens. Med. 2023;4: 191-215.e9. doi:10.1016/j.medj.2023.02.004
- 44. Fraley E, LeMaster C, Banerjee D, Khanal S, Selvarangan R, Bradley T. Cross-reactive
 antibody immunity against SARS-CoV-2 in children and adults. Cell Mol Immunol.
 2021;18: 1826–1828. doi:10.1038/s41423-021-00700-0
- 678 45. Children develop robust and sustained cross-reactive spike-specific immune responses
 679 to SARS-CoV-2 infection | Nature Immunology. [cited 15 Feb 2023]. Available:
 680 https://www.nature.com/articles/s41590-021-01089-8
- 46. Snapiri O, Rosenberg Danziger C, Shirman N, Weissbach A, Lowenthal A, Ayalon I, et al.
 Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19
 Vaccine. Pediatr Infect Dis J. 2021;40: e360–e363. doi:10.1097/INF.00000000003235

- 47. Sparks R, Lau WW, Liu C, Han KL, Vrindten KL, Sun G, et al. Influenza vaccination reveals
 sex dimorphic imprints of prior mild COVID-19. Nature. 2023; 1–3.
 doi:10.1038/s41586-022-05670-5
- 48. Hall KT, Stone VE, Ojikutu B. Reactogenicity and Concomitant Administration of the
 COVID-19 Booster and Influenza Vaccine. JAMA Network Open. 2022;5: e2222246.
 doi:10.1001/jamanetworkopen.2022.22246
- 49. Izikson R, Brune D, Bolduc J-S, Bourron P, Fournier M, Moore TM, et al. Safety and
 immunogenicity of a high-dose quadrivalent influenza vaccine administered
 concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged
 >65 years: a phase 2, randomised, open-label study. The Lancet Respiratory Medicine.
 2022;10: 392-402. doi:10.1016/S2213-2600(21)00557-9
- 50. Negriff S, Susman EJ. Pubertal Timing, Depression, and Externalizing Problems: A
 Framework, Review, and Examination of Gender Differences. Journal of Research on
 Adolescence. 2011;21: 717–746. doi:10.1111/j.1532-7795.2010.00708.x
- 698 51. Ogbe A, Kronsteiner B, Skelly DT, Pace M, Brown A, Adland E, et al. T cell assays
 699 differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral
 700 responses. Nat Commun. 2021;12: 2055. doi:10.1038/s41467-021-21856-3

702 Figure 1: Characteristics of the study cohort. 34 adolescents were enrolled and provided

703 consent, of which 18 were seropositive for S or N pre-V1. Samples were taken pre-V1 on the

704 day of vaccination, a mean of 37 days post-V1, mean 2 days pre-V2, and mean 35 days post-

705 V2 (A). The median age was 13 years 1 month for females (orange) and 14 years and 5



709 Figure 2: Humoral responses following first and second doses of BNT162b2 in previously-

- 710 infected and infection-naive adolescents.
- 711 Anti-S, RBD and N IgG in infection-naive (grey) and previously-infected (red) adolescents (A).
- 712 Thresholds for IgG positivity were taken from previous literature. [26] nAbs targeting S in
- 713 infection-naïve (grey) and previously-infected (red) adolescents using MSD ACE2-Spike
- 714 binding inhibition assays (B). Percent inhibition of SARS-CoV-2 S-ACE2 binding as measured
- 715 by MSD ACE2 inhibition assay in infection-naive (grey) and previously-infected (red)
- 716 adolescents targeting common SARS-CoV-2 lineages: Wuhan, B.1.351 (Beta), B.1.617.2/AY.4
- 717 (Delta), BA.4 and BA.5 (Omicron) (C). P-values from Wilcoxon signed-rank tests. Fold change
- 718 refers to the difference in total group medians.



721 Figure 3: T-cell responses to SARS-CoV-2 S are boosted post-V1 and post-V2

722 CellTrace Violet stains were used to assess proliferating CD4+ and CD8+ T-cells targeting the

- 723 S1 region of S (A), the S2 region of S (B), M (C) and N (D) in infection-naive (grey) and
- 724 previously-infected (red) individuals (A). Data shows proliferating cells as a percentage of
- parent populations with DMSO background values subtracted. Thresholds for positivity were
- set at 1 as determined by previous literature.⁴⁹ P-values from Wilcoxon signed-rank tests.
- Fold change refers to the difference in total group medians. Values below 1% were givennominal values of 0.9%.
 - S2 **S1** В A cells % proliferating CD4+ cells cells 15 cells 30 p=0.03 % proliferating CD8+ CD4+ proliferating CD8+ 10 p=0.02 % proliferating (20 5 10 % 0 n Post-V1 Pre-V2 Post V2 Post V1 Pre-V2 Post V2 Pre-V1 Post-V1 Pre-V2 Post-V2 Pre-V1 Post-V1 Pre-V2 Post-V2 Pre-V1 Pre-V1 proliferating CD4+ cells proliferating CD4+ cells proliferating CD8+ cells 40 proliferating CD8+ 30 30 20 20 10 10 % % 0 % 0 % 0 Post-V2 Pre-V1 Post-V1 Pre-V2 Pre-V1 Post-V1 Pre-V2 Post-V2 Pre-V1 Post-V1 Pre-V2 Post-V2 Pre-V1 Post-V1 Pre-V2 Post V2 С М D Ν proliferating CD4+ cells - cells proliferating CD8+ cells proliferating CD8+ cells proliferating CD4+ 4 % % % % Pre-V1 Post-V1 Pre-V2 Post-V2 Pre-V1 Post-V1 Pre-V2 Post-V2 Pre-V1 Post-V1 Pre-V2 Post-V2 Pre-V1 Post-V1 Pre-V2 Post-V2 cells 30 proliferating CD8+ cells cells proliferating CD8+ cells proliferating CD4+ proliferating CD4+ 20 , % % % % Pre-V1 Post-V Pre-V2 Post-V2 Pre-V1 Post-V1 Pre-V2 Post-V2 Pre-V1 Post-V1 Pre-V2 Post-V2 Pre-V1 Post-V1 Pre-V2 Post-V2 infection-naïve 🔴 previously infected .

731 Figure 4: Age-specific effects in the humoral response to BNT162b2

- 732 IgG targeting S in infection-naïve adolescents (grey circles), infection-naïve adults (32-52
- 733 years) (grey squares), previously-infected adolescents (red circles) and previously-infected
- adults (red squares), pre-V1 (unfilled shapes) and post-V1 (filled shapes) as measured by an
- 735 MSD v-plex immunoassay (A). nAb concentration targeting S in infection-naïve and
- 736 previously-infected adolescents and adults as measured by an MSD ACE2-Spike binding
- 737 immunoassay (B). The ratio of IgG targeting HCoV-OC43 S to SARS-CoV-2 S (C) and the ratio
- 738 of IgG targeting HCoV-HKU1 S to SARS-CoV-2 S (D) in infection-naive adolescents (grey
- 739 circles), infection-naive adults (grey squares), previously-infected adolescents (red circles),
- and previously-infected adults (red squares). P-values represent Mann-Whitney test values
- 741 for unpaired data, and Wilcoxon signed-rank test values for paired data. Fold change
- 742 calculated as the ratio of population medians.



744 745

746 Figure 5: Infection-naïve males generate greater post-V1 IgG responses than females

- 747 IgG targeting S (A) and RBD (B) in infection-naive adolescents pre-V1 (unfilled circles) and
- post-V1 (filled circles) in females (orange circles) and males (blue circles) as measured by an
- 749 MSD v-plex immunoassay. IgG targeting S (C) and RBD (D) in previously-infected adolescents
- **750** pre-V1 and post-V1 in females and males. Concentration of nAbs targeting S (E) and RBD (F)
- in infection-naive adolescents as measured by an MSD ACE2-Spike binding inhibition assay.
- 752 Concentration of nAbs targeting S (G) and RBD (H) in previously-infected adolescents. P-
- values represent Wilcoxon test values for paired data and Mann-Whitney test values for
- **754** unpaired data. Fold change calculated as the ratio of population medians.



757 Figure 6: Age- and sex-specific immunity to influenza following LAIV administration

- 758 IgG targeting haemagglutinin (HA) pre- (unfilled circles) and post- (filled circles) LAIV
- 759 administration for the four influenza lineages (A) (P-values from Wilcoxon tests). The
- 760 correlation between age and IgG targeting HA for the B/Washington lineage pre-LAIV (**B**) and
- 761 post-LAIV (C) (Spearman rank r- and p-values). IgG targeting SARS-CoV-2 S (D) and RBD (E) in
- infection-naïve (grey) and previously-infected (red) adolescents who received the BNT162b2
- vaccine alone (BNT), or co-administered with the LAIV (LAIV + BNT) (Mann-Whitney p-values).
- 764 IgG targeting HA pre- (unfilled circles) and post- (filled cirles) LAIV administration in males
- 765 (blue) and females (orange) for the four influenza lineages (F-I) (Wilcoxon p-values).

